Results 21 to 30 of about 11,764 (177)

Sequential occurrence of thrombotic thrombocytopenic purpura, essential thrombocythemia, and idiopathic thrombocytopenic purpura in a 42-year-old African-American woman: a case report and review of the literature

open access: yesJournal of Medical Case Reports, 2012
Introduction Thrombotic thrombocytopenic purpura and idiopathic thrombocytopenic purpura are two well recognized syndromes that are characterized by low platelet counts. In contrast, essential thrombocythemia is a myeloproliferative disease characterized
Farhat Mirna H   +3 more
doaj   +1 more source

ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission

open access: yesHaematologica, 2008
Background From 20 to 50% of patients who survive an acute episode of the acquired form of thrombotic thrombocytopenic purpura relapse but clinical and laboratory markers of recurrence are not well established.Design and Methods In 109 patients enrolled ...
Flora Peyvandi   +15 more
doaj   +1 more source

Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura

open access: yesKidney International Reports, 2017
Severe acute kidney injury (AKI) and chronic kidney disease (CKD) are considered to be uncommon in patients with acquired thrombotic thrombocytopenic purpura.
Dustin J. Little   +5 more
doaj   +1 more source

Perinatal outcomes in normotensive versus hypertensive HELLP syndrome

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To compare maternal and neonatal outcomes between women with hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome with and without associated hypertension. Methods This was a retrospective cohort study at a tertiary university‐affiliated medical center including all singleton HELLP cases >24 weeks gestation (January ...
Matan Anteby   +4 more
wiley   +1 more source

Graves disease-induced thrombotic thrombocytopenic purpura: a case report

open access: yesJournal of Medical Case Reports, 2019
Background Thrombotic thrombocytopenic purpura is an autoimmune disease that carries a high mortality. Very few case reports in the literature have described a relationship between Graves disease and thrombotic thrombocytopenic purpura. We present a case
Saira Chaughtai   +6 more
doaj   +1 more source

Prognostic factors in thrombotic thrombocytopenic purpura

open access: yesTürk Biyokimya Dergisi, 2022
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy with no standardized prognostic model to predict mortality. The aim of the study is to determine parameters associated with TTP-related mortality.
Yalçıner Merih, İlhan Osman
doaj   +1 more source

Thrombocytopenic Thrombotic Pupura Presenting with Neurological Symptoms : A Case Report

open access: yesTurkish Journal of Internal Medicine, 2022
Thrombotic thrombocytopenic purpura (TTP) is thrombotic microangiopathy caused by decreased activity of ADAMTS13, a von Willebrand factor-degrading metalloprotease.
Yağmur Çakır   +3 more
doaj   +1 more source

Role of defensins in immunothrombosis

open access: yesRheumatology &Autoimmunity, EarlyView.
Defensins are important proteins that link the immune system and blood clotting, playing a key role in immunothrombosis. α‐defensins mainly come from neutrophils, while β‐defensins are produced by epithelial cells and platelets. These proteins help form blood clots in several ways: they slow down clot breakdown (fibrinolysis), activate platelets, and ...
Yuebing Wang   +7 more
wiley   +1 more source

Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain

open access: yesHaematologica, 2011
Background The majority of patients diagnosed with thrombotic thrombocytopenic purpura have autoantibodies directed towards the spacer domain of ADAMTS13.Design and Methods In this study we explored the epitope specificity and immunoglobulin class and ...
Wouter Pos   +6 more
doaj   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

open access: yesVIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Home - About - Disclaimer - Privacy